Product Overview
[Drug Name]
Generic Name: Olmesartan Medoxomil Tablets
Trade Name: NuoDe Pharmaceutical Olmesartan Medoxomil Tablets 20mg*28 Tablets
Pinyin Full Code: NuoDeYaoYe AoMeiShaTanZuoPian 20mg*28 Tablets
[Main Ingredients]
The main ingredient of this product is Olmesartan Medoxomil. Chemical Name: 2,3-Dihydroxy-2-butenyl-4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-phenyl)benzyl]imidazole-5-carboxylate, cyclo[2,3-carbonic acid]. Molecular Formula: C29H30N6O6. Molecular Weight: 558.59.
[Properties]
This product is a white or off-white film-coated tablet. After removing the coating, it appears white or off-white.
[Indications/Main Functions]
This product is indicated for the treatment of hypertension. Hypertension control is part of comprehensive cardiovascular risk management, which may include lipid control, diabetes management, antithrombotic therapy, smoking cessation, physical exercise, and sodium restriction. Increases in either systolic or diastolic blood pressure increase cardiovascular risk. The absolute risk increase per mmHg increase is greater at higher baseline blood pressure levels. The relative magnitude of risk reduction achieved by lowering blood pressure is similar among individuals with varying absolute cardiovascular risk. In patients with severe hypertension, even a small reduction in blood pressure can provide a significant clinical benefit. In adults with hypertension, lowering blood pressure generally reduces the risk of cardiovascular events, primarily stroke and myocardial infarction. However, there is no controlled clinical evidence that this product reduces cardiovascular risk.
[Specification]
20mg*28 tablets
[Dosage and Administration]
The dosage should be individualized. In normovolemic patients, as monotherapy, the recommended starting dose is 20mg once daily. For patients who require further blood pressure lowering after two weeks of treatment, the dose can be increased to 40mg. Doses greater than 40mg have not demonstrated a greater antihypertensive effect. When the daily dose is the same, twice-daily dosing has not been shown to be superior to once-daily dosing. This product can be taken with or without food. This product can be used in combination with other diuretics and other antihypertensive drugs. No dose adjustment is required for elderly patients and patients with moderate to significant hepatic or renal impairment (creatinine clearance <40 mL/minute) (see Special Populations under [Pharmacokinetics]). Olmesartan medoxomil should be used under close medical supervision in patients with potential volume depletion (e.g., those receiving diuretic therapy, especially those with renal impairment), and a lower starting dose may be considered.
[Adverse Reactions]
See the package insert for details.
[Contraindications]
This product is contraindicated in patients with allergies to its ingredients. This product should not be used in combination with aliskiren in patients with diabetes.
[Precautions]
See the package insert for details.
